Which imaging tests are recommended for diagnosing Alzheimer disease and Lewy body dementia?

Imaging Tests for Alzheimer's Disease and Lewy Body Dementia

MRI head without IV contrast is the foundational imaging study for both Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), while dopamine transporter SPECT (DAT-SPECT) is the single most accurate test for distinguishing DLB from AD. 1

Initial Structural Imaging

MRI Head Without IV Contrast

MRI without contrast is the primary structural imaging modality for both conditions and should be obtained first. 1

• For AD: Demonstrates regional atrophy patterns with earliest volume loss in the entorhinal cortex, followed by hippocampal atrophy that correlates with tau deposition 1
• For DLB: Shows less pronounced mesial temporal lobe and hippocampal atrophy compared to AD, which helps differentiate the two conditions 1
• Critical for treatment planning: Brain MRI is mandatory if antiamyloid monoclonal antibody therapy is being considered for AD 1
• Excludes mimics: Identifies treatable structural lesions (subdural hematomas, mass lesions, neoplasms) that may present with similar symptoms 1

CT Head Without IV Contrast

• Alternative when MRI unavailable: Can demonstrate hippocampal atrophy patterns and exclude structural lesions, though less sensitive than MRI 1
• CT with contrast has no role in dementia evaluation 1

Functional and Molecular Imaging

For Alzheimer's Disease

Amyloid PET/CT is the highest-yield advanced imaging for AD, particularly in atypical presentations. 1

• Diagnostic accuracy: Positive in >86% of AD patients with high specificity; demonstrates symmetric, diffuse cortical uptake with cerebellar sparing 1
• When most useful: Young patients (<65 years), atypical presentations (nonamnestic, rapid/slow progression), and uncertain etiology where it changes diagnosis in 67% and management in 80% of cases 1
• Combined approach: When used with FDG-PET/CT, achieves 97% sensitivity and 98% specificity for AD pathology 1
• Treatment requirement: Positive amyloid PET/CT is mandatory before initiating antiamyloid monoclonal antibody therapy 1
• Exclusionary value: Negative amyloid PET/CT effectively excludes AD diagnosis 1

FDG-PET/CT for AD shows hypometabolism in parietal and temporal lobes, precuneus, and posterior cingulate gyrus with 95% sensitivity and 73% specificity for differentiating AD from non-AD dementias 1

For Dementia with Lewy Bodies

Dopamine transporter SPECT (DAT-SPECT) is the most accurate imaging test for DLB diagnosis and differentiation from AD. 1, 2

• Diagnostic superiority: DAT-SPECT enables significantly more accurate differentiation of DLB from AD than all other neuroimaging techniques, including MRI, perfusion SPECT, and cardiac MIBG scintigraphy 2
• Mechanism: Demonstrates reduced striatal dopamine transporter activity in DLB; normal striatal uptake helps distinguish AD from DLB 1
• Limitation: Not useful at the prodromal/MCI stage 3

FDG-PET/CT for DLB demonstrates distinctive patterns: 1

• Hypometabolism in temporal, parietal, and occipital lobes plus cerebellum
• "Cingulate island sign" (preserved posterior cingulate metabolism) is a specific biomarker for DLB that distinguishes it from AD 1
• Occipital lobe hypometabolism is the key distinguishing feature from AD 1, 4

Cardiac MIBG scintigraphy shows decreased cardiac sympathetic activity in DLB and provides better discrimination than MRI or perfusion SPECT, though less accurate than DAT-SPECT 1, 2

Practical Diagnostic Algorithm

Step 1: Obtain MRI head without contrast

• Assess atrophy patterns
• Exclude structural mimics
• Required baseline if treatment anticipated

Step 2: For suspected AD with typical presentation

• Consider FDG-PET/CT if diagnosis uncertain (shows temporoparietal hypometabolism) 1
• Obtain amyloid PET/CT if: age <65 years, atypical features, uncertain etiology, or antiamyloid therapy being considered 1

Step 3: For suspected DLB

• Obtain DAT-SPECT as the definitive test to confirm DLB and differentiate from AD 1, 2
• Consider FDG-PET/CT to look for cingulate island sign and occipital hypometabolism 1
• Cardiac MIBG scintigraphy provides supportive evidence 1, 2

Step 4: When both conditions suspected (mixed dementia)

• Amyloid PET/CT can be positive in up to 29% of DLB patients (63% if >80 years old), though binding is lower than pure AD 1
• Mixed dementia should be considered when amyloid and FDG-PET/CT findings are incongruent 1
• Combined MRI and SPECT achieves higher diagnostic accuracy (AUC 0.898) than either modality alone 5

Critical Caveats

• Amyloid PET/CT is rarely appropriate for patients with conclusive CSF biomarkers or established DLB diagnosis 1
• Brain perfusion SPECT has lower sensitivity than clinical criteria for AD and is considered adjunctive only 1
• Functional MRI shows promise with abnormal default mode network connectivity in AD but is not yet validated for routine clinical practice 1
• Sex differences matter: Females with LB pathology may have faster cognitive decline and less prominent parkinsonism, making differentiation from AD more challenging 6